SCHEMBL174173

SCHEMBL174173

N=C(N)N(Cc1ccccc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.62
TAS2R14 Q9NYV8 8/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CNR2 P34972 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
PTPN1 P18031 1/20 0.46
ESR1 P03372 1/20 0.45
CA2 P00918 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CXCR3 P49682 1/20 0.43
NR1I2 O75469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984791 0.76 TAS2R14 (0.71) HSD11B1TAS2R14MEN1KMT2ACNR2
SCHEMBL31220506 0.73 HSD11B1 (0.61) HSD11B1TAS2R14MEN1KMT2ACNR2
SCHEMBL6411443 0.73 HSD11B1 (0.61) HSD11B1TAS2R14MEN1KMT2AESR1
SCHEMBL9503189 0.73 APOBEC3G (0.47) HSD11B1KMT2AESR1CA2ALDH1A1
SCHEMBL29111496 0.73 APOBEC3G (0.47) HSD11B1KMT2AESR1CA2ALDH1A1
SCHEMBL7665734 0.73 HSD11B1 (0.57) HSD11B1TAS2R14MEN1KMT2ACNR2
SCHEMBL28308667 0.72 SERPINE1 (0.64) HSD11B1TAS2R14MEN1KMT2ACNR2
SCHEMBL11856727 0.72 HSD11B1 (0.60) HSD11B1TAS2R14MEN1KMT2ACNR2
Sulfuric Acid SCHEMBL10702872 0.71 GRIN2D (0.47) HSD11B1TAS2R14MEN1KMT2AGRIN2D
Sulfuric Acid SCHEMBL8557206 0.71 NPC1 (0.56) MEN1KMT2AGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676721-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2017-06-13 US disclosed
US-20130295051-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2013-11-07 US disclosed
EP-2611778-A1 GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Forma TM, LLC. (US) 2013-07-10 EP disclosed
WO-2012031199-A1 GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA THERAPEUTICS, INC. (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130295051-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 HSD11B1 2589/4885TAS2R14 2889/4885MEN1 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.